Seattle-based Theraclone Sciences is merging with Annapolis, Md.-based PharmAthene, a biodefense drug developer.
Theraclone CEO Clifford Stocks will head the newly merged company, which will be headquartered in Seattle and retain the name of publicly traded PharmAthene.
PharmAthene CEO Eric Richman will become a board member once the deal is complete.
Theraclone is a startup that’s been working on a flu therapy treatment. Earlier this year it raised $14 million in funding to support its work.
The…
Seattle-based Theraclone Sciences is merging with Annapolis, Md.-based PharmAthene, a biodefense drug developer.
Theraclone CEO Clifford Stocks will head the newly merged company, which will be headquartered in Seattle and retain the name of publicly traded PharmAthene.
PharmAthene CEO Eric Richman will become a board member once the deal is complete.
Theraclone is a startup that’s been working on a flu therapy treatment. Earlier this year it raised $14 million in funding to support its work.
The…